OMA Guidelines Bundle

Obesity-Related Diseases 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544298

Contents of this Issue

Navigation

Page 37 of 45

38 Management Obesity and Cardiovascular Disease Medical Management of Hypertension   ➤ Select an antihypertensive medication based on a compelling indication. If there is no primary indication, then first-line antihypertensive medications include thiazide diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs).   ➤ For individuals with diabetes or chronic kidney disease, consider starting an ACE inhibitor or an ARB.   ➤ β-blockers should be started as a first-line antihypertensive medication only for individuals who have ischemic heart disease or heart failure. Some β-blockers are associated with weight gain.   ➤ Second-line antihypertensive medications include loop diuretics, potassium-sparing diuretics, mineralocorticoid receptor antagonists, direct renin inhibitors, α-blockers, and vasodilators.   ➤ For stage 1 hypertension, initiation of a single antihypertensive medication with dose titration is reasonable.   ➤ For stage 2 hypertension, initiation of two first-line antihypertensive medications is reasonable.   ➤ With weight loss, monitor blood pressure closely and adjust antihypertensive medications to prevent hypotension.   ➤ Consider referral to cardiology if hypertension is not well controlled despite titration of medications or concerns for resistant hypertension.   ➤ Consider referral to pediatric cardiology for treatment of hypertension in children.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity-Related Diseases 2026